JPH06506446A - 腫瘍壊死因子媒介疾患の治療方法 - Google Patents
腫瘍壊死因子媒介疾患の治療方法Info
- Publication number
- JPH06506446A JPH06506446A JP4504597A JP50459792A JPH06506446A JP H06506446 A JPH06506446 A JP H06506446A JP 4504597 A JP4504597 A JP 4504597A JP 50459792 A JP50459792 A JP 50459792A JP H06506446 A JPH06506446 A JP H06506446A
- Authority
- JP
- Japan
- Prior art keywords
- tnf
- tnf inhibitor
- inhibitor
- 40kda
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (39)
- 1.治療的に有効な量のTNF阻害剤を、それを必要とする患者に投与すること を含む、TNF媒介疾患を治療する方法。
- 2.当該TNF阻害剤は蛋白質である、請求の範囲第1項記載の方法。
- 3.当該TrNF阻害剤は30KDaTNF阻害剤である、請求の範囲第2項記 載の方法。
- 4.当該TNF阻害剤は40KDaTNF阻害剤である、請求の範囲第2項記載 の方法。
- 5.当該40KDaTNF阻害剤は、全長40KDaTNF阻害剤、40KDa TNF阻害剤Δ51、及び40KDaTNF阻害剤Δ53からなる群からの少な くとも1つの化合物を含む、請求の範囲第4項記載の方法。
- 6.当該40KDaTNF阻害剤は全長40KDaTNF阻害剤である、請求の 範囲第4項記載の方法。
- 7.当該40KDaTNF阻害剤は40KDaTNF阻害剤Δ51である、請求 の範囲第4項記載の方法。
- 8.当該40KDaTNF阻害剤は40KDaTNF阻害剤Δ53である請求の 範囲第4項記載の方法。
- 9.当該TNF阻害剤は組換えDNA法により産生される、請求の範囲第2項記 載の方法。
- 10.当該TNF阻害剤は実質的に純粋な形で産生される、請求の範囲第9項記 載の方法。
- 11.当該TNF阻害剤は30KDaTNF阻害剤のムテインである、請求の範 囲第2項記載の方法。
- 12.当該TNF阻害割はC10530KDaTNF阻害剤である、請求の範囲 第11項記載の方法。
- 13.当該TNF阻害剤は30KDaTNF阻害剤−PEG化合物である、請求 の範囲第2項記載の方法。
- 14.当該TNF阻害剤はC105−PEG 3400dbである、請求の範囲 第13項記載の方法。
- 15.当該TNF阻害剤は薬剤学的に許容できる担体で投与される、請求の範囲 第1項記載の方法。
- 16.当該TNF阻害剤は液体の形で投与される、請求の範囲第1項記載の方法 。
- 17.当該TNF阻害剤はTNF結合蛋白質である、請求の範囲第1項記載の方 法。
- 18.当該TNF阻害剤はTNF受容体のフラグメントである、請求の範囲第1 項記載の方法。
- 19.当該TNF媒介疾患は、成人呼吸困難症候群、肺線維症、関節炎、敗血症 ショック及び炎症性腸疾患からなる群から選ばれる、請求の範囲第1項記載の方 法。
- 20.当該TNF媒介疾患は敗血症ショックである、請求の範囲第1項記載の方 法。
- 21.当該TNF媒介疾患は関節炎である、請求の範囲第1項記載の方法。
- 22.当該TNF媒介疾患は成人呼吸困難症候群である請求の範囲第1項記載の 方法。
- 23.治療的に有効な量のTNF阻害剤を、それを必要とする患者に投与するこ と を含む、TNF媒介疾患を予防する方法。
- 24.当該TNF阻害剤は30KDaTNF阻害剤である請求の範囲第23項記 載の方法。
- 25.当該TNF阻害割は40KDaTNF阻害剤である請求の範囲第23項記 載の方法。
- 26.当該40KDaTNF阻害剤は、全長40KDaTNF阻害剤、40KD aTNF阻害剤(Δ51及び40KDaTNF阻害剤Δ53からなる群から選ば れる、請求の範囲第25項記載の方法。
- 27.当該40KDaTNF阻害剤は全長40KDaTNF阻害剤である、請求 の範囲第25項記載の方法。
- 28.当該40KDaTNF阻害剤は40KDaTNF阻害剤Δ51である、請 求の範囲第25項記載の方法。
- 29.当該40KDaTNF阻害剤は40KDaTNF阻害剤Δ53である、請 求の範囲第25項記載の方法。
- 30.当該TNF阻害剤はTNF結合蛋白質である、請求の範囲第25項記載の 方法。
- 31.当該TNF阻害剤は組換えDNA法により産生される、請求の範囲第25 項記載の方法。
- 32.当該TNF媒介疾患は、成人呼吸困難症候群、肺線維症、関節炎.敗血症 ショック及び炎症性腸疾患からなろ群から選ばれる、請求の範囲第25項記載の 方法。
- 33.当該TNF媒介疾患は敗血症ショックである、請求の範囲第25項記載の 方法。
- 34.当該TNF阻害剤は30KDaTNF阻害剤のムテインである、請求の範 囲第25項記載の方法。
- 35.当該TNF阻害剤はC10530KDaTNF阻害剤である、請求の範囲 第24項記載の方法。
- 36.当該TNF阻害割は30KDaTNF阻害剤−PEG化合物である、請求 の範囲第25項記載の方法。
- 37.当該TNF阻害剤はC105−PEG 3400dbである、請求の範囲 第36項記載の方法。
- 38.当該TNF媒介疾患は関節炎である、請求の範囲第25項記載の方法。
- 39.当該TNF媒介疾患は成人呼吸困難症候群である請求の範囲第25項記載 の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64434591A | 1991-01-18 | 1991-01-18 | |
US644,345 | 1991-01-18 | ||
PCT/US1992/000432 WO1992013095A1 (en) | 1991-01-18 | 1992-01-17 | Methods for treating tumor necrosis factor mediated diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP29598898A Division JP3210629B2 (ja) | 1991-01-18 | 1998-09-10 | 腫瘍壊死因子媒介疾患の治療または予防用薬剤学的組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06506446A true JPH06506446A (ja) | 1994-07-21 |
JP2864434B2 JP2864434B2 (ja) | 1999-03-03 |
Family
ID=24584497
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4504597A Expired - Lifetime JP2864434B2 (ja) | 1991-01-18 | 1992-01-17 | 腫瘍壊死因子媒介疾患の治療方法 |
JP29598898A Expired - Lifetime JP3210629B2 (ja) | 1991-01-18 | 1998-09-10 | 腫瘍壊死因子媒介疾患の治療または予防用薬剤学的組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP29598898A Expired - Lifetime JP3210629B2 (ja) | 1991-01-18 | 1998-09-10 | 腫瘍壊死因子媒介疾患の治療または予防用薬剤学的組成物 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0567566B2 (ja) |
JP (2) | JP2864434B2 (ja) |
KR (1) | KR100234520B1 (ja) |
AT (1) | ATE190629T1 (ja) |
AU (2) | AU1235692A (ja) |
CA (1) | CA2100329C (ja) |
DE (1) | DE69230789T3 (ja) |
DK (1) | DK0567566T4 (ja) |
ES (1) | ES2145744T5 (ja) |
GE (1) | GEP20002142B (ja) |
GR (1) | GR3033327T3 (ja) |
NO (1) | NO316310B1 (ja) |
RU (1) | RU2166955C2 (ja) |
SG (1) | SG63617A1 (ja) |
WO (1) | WO1992013095A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002528392A (ja) * | 1998-10-20 | 2002-09-03 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用 |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5512544A (en) * | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
EP0393438B1 (de) * | 1989-04-21 | 2005-02-16 | Amgen Inc. | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
US6221675B1 (en) | 1989-04-21 | 2001-04-24 | Amgen, Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
ATE236249T1 (de) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
CA2121473C (en) * | 1991-10-15 | 2001-05-01 | Michael Mullarkey | Methods and compositions for treating allergic reactions |
JPH07509223A (ja) * | 1992-04-30 | 1995-10-12 | アムジェン インコーポレイテッド | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
WO1994006476A1 (en) * | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US5457129A (en) * | 1993-05-17 | 1995-10-10 | Research Development Foundation | Inhibition of nitric oxide production by retinoic acid |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
US5629384A (en) * | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US7012060B1 (en) | 1995-07-14 | 2006-03-14 | Applied Research Systems Ars Holding N.V. | TNF receptor and steroid hormone in a combined therapy |
ES2171547T3 (es) * | 1995-07-14 | 2002-09-16 | Applied Research Systems | Receptor de tnf y hormona esteroidica dhea en terapia combinada. |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
DK0942740T3 (da) | 1996-12-06 | 2003-12-15 | Amgen Inc | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme |
EP2002846B1 (en) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
CA2310575A1 (en) * | 1997-11-07 | 1999-05-20 | Uab Research Foundation | Method for the augmentation of gene expression |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
EP1259616A2 (en) | 2000-03-02 | 2002-11-27 | Xencor | Tnf-alpha variants for the treatment of tnf-alpha related disorders |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
EP3492100B1 (en) | 2001-06-26 | 2021-12-08 | Amgen Inc. | Antibodies to opgl |
TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
WO2003084560A2 (en) | 2002-04-10 | 2003-10-16 | Applied Research Systems Ars Holding N.V. | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
US7585840B2 (en) | 2002-04-10 | 2009-09-08 | Merck Serono S.A. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
UA86750C2 (ru) | 2002-10-08 | 2009-05-25 | Арес Трейдінг С.А. | Применение il-1f7b, способного связываться с il-18r и il-18bp, вместе с il-18bp для лечения заболеваний, ассоциированных с избыточной активностью il-18 |
US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
IL161673A0 (en) | 2004-04-29 | 2004-09-27 | Applied Research Systems | Compositions and methods for therapy of chemotherapy-induced neuropathy |
IL161672A0 (en) | 2004-04-29 | 2004-09-27 | Yeda Res & Dev | Compositions and methods for therapy of chemotherapy-induced neuropathy |
CA2603671C (en) | 2005-04-26 | 2012-03-27 | Laboratoires Serono S.A. | Insp163 polypeptides for the treatment or prevention of cancer and arthritis |
PL2267024T3 (pl) | 2005-06-03 | 2012-10-31 | Ares Trading Sa | Wytwarzanie rekombinowanego białka wiążącego IL-18 |
RS52273B (en) | 2005-06-10 | 2012-10-31 | Ares Trading S.A. | PROCESS FOR PURIFICATION OF IL-18 BINDING PROTEIN |
BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 jnk 억제제 |
DK1917276T3 (en) | 2005-08-26 | 2018-05-07 | Ares Trading Sa | Process for Preparation of Glycosylated Interferon Beta |
ZA200801923B (en) | 2005-09-01 | 2009-09-30 | Ares Trading Sa | Treatment of optic neuritis |
KR20080060226A (ko) | 2005-10-31 | 2008-07-01 | 라보라토리스 세로노 에스.에이. | 신경 질환의 치료 및/또는 예방을 위한 sdf-1의 용도 |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
IL173104A0 (en) | 2006-01-12 | 2006-06-11 | Yeda Res & Dev | Siva and ubiquintination |
EA020805B1 (ru) | 2006-05-24 | 2015-01-30 | Мерк Сероно С.А. | Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
AU2008208837A1 (en) | 2007-01-26 | 2008-07-31 | Merck Serono S.A. | Purification of Fc-TACT fusion proteins using the oilbody technology |
US20100256337A1 (en) | 2007-10-22 | 2010-10-07 | Merck Serono Sa | Method for purifying an fc-containing protein |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
CN102448991B (zh) | 2009-03-30 | 2016-09-14 | 安迪穆生物科技有限公司 | 分离的激动剂型抗edar单克隆抗体的制备 |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
CN102821787B (zh) | 2010-01-15 | 2015-07-29 | 麒麟-安姆根有限公司 | 抗体制剂和治疗方案 |
WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
US9597325B2 (en) | 2010-10-13 | 2017-03-21 | Trustees Of Boston University | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
EP3461482A1 (en) | 2012-03-16 | 2019-04-03 | Children's Medical Center Corporation | Calcium channel blockers for the treatment of ribosomal disorders and ribosomapathies |
US9751942B2 (en) | 2012-03-29 | 2017-09-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-LAMP5 antibody and utilization thereof |
RU2731713C2 (ru) | 2013-09-05 | 2020-09-08 | Аб2 Био Са | Применение il-18-связывающего белка (il-18bp) при воспалительных заболеваниях |
KR20160130248A (ko) | 2014-03-31 | 2016-11-10 | 키린-암젠, 인코포레이티드 | 손발톱 및 두피 건선의 치료 방법 |
SG11201706879UA (en) | 2015-03-05 | 2017-09-28 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
US10980808B2 (en) | 2016-07-13 | 2021-04-20 | The Children's Medical Center Corporation | Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies |
WO2018140121A1 (en) | 2017-01-30 | 2018-08-02 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
AU2017398101A1 (en) | 2017-02-07 | 2019-08-01 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
CN113874073A (zh) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 |
EP4146174A1 (en) | 2020-05-06 | 2023-03-15 | AB2 Bio SA | Il-18 binding protein (il-18bp) in respiratory diseases |
EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
WO2023166206A1 (en) | 2022-03-04 | 2023-09-07 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in the treatment of vexas |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1283046C (en) * | 1986-05-29 | 1991-04-16 | Nandini Katre | Tumor necrosis factor formulation |
IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
GB8807803D0 (en) * | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
EP0393438B1 (de) * | 1989-04-21 | 2005-02-16 | Amgen Inc. | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
DE3922089A1 (de) * | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
ATE240740T1 (de) * | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
-
1992
- 1992-01-17 RU RU93051522/14A patent/RU2166955C2/ru active
- 1992-01-17 GE GEAP19922664A patent/GEP20002142B/en unknown
- 1992-01-17 WO PCT/US1992/000432 patent/WO1992013095A1/en active IP Right Grant
- 1992-01-17 DK DK92904429T patent/DK0567566T4/da active
- 1992-01-17 CA CA002100329A patent/CA2100329C/en not_active Expired - Lifetime
- 1992-01-17 JP JP4504597A patent/JP2864434B2/ja not_active Expired - Lifetime
- 1992-01-17 ES ES92904429T patent/ES2145744T5/es not_active Expired - Lifetime
- 1992-01-17 KR KR1019930702129A patent/KR100234520B1/ko not_active IP Right Cessation
- 1992-01-17 EP EP92904429A patent/EP0567566B2/en not_active Expired - Lifetime
- 1992-01-17 SG SG1996007283A patent/SG63617A1/en unknown
- 1992-01-17 AU AU12356/92A patent/AU1235692A/en not_active Abandoned
- 1992-01-17 DE DE69230789T patent/DE69230789T3/de not_active Expired - Lifetime
- 1992-01-17 AT AT92904429T patent/ATE190629T1/de not_active IP Right Cessation
-
1993
- 1993-07-19 NO NO19932610A patent/NO316310B1/no not_active IP Right Cessation
-
1996
- 1996-02-02 AU AU42288/96A patent/AU702466B2/en not_active Withdrawn - After Issue
-
1998
- 1998-09-10 JP JP29598898A patent/JP3210629B2/ja not_active Expired - Lifetime
-
2000
- 2000-04-26 GR GR20000401011T patent/GR3033327T3/el unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002528392A (ja) * | 1998-10-20 | 2002-09-03 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用 |
JP2010222364A (ja) * | 1998-10-20 | 2010-10-07 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用 |
Also Published As
Publication number | Publication date |
---|---|
RU2166955C2 (ru) | 2001-05-20 |
ATE190629T1 (de) | 2000-04-15 |
CA2100329A1 (en) | 1992-07-19 |
AU4228896A (en) | 1996-04-18 |
DK0567566T3 (da) | 2000-07-31 |
DK0567566T4 (da) | 2007-10-22 |
EP0567566B1 (en) | 2000-03-15 |
DE69230789D1 (de) | 2000-04-20 |
NO932610L (no) | 1993-09-09 |
CA2100329C (en) | 2009-09-29 |
AU702466B2 (en) | 1999-02-25 |
DE69230789T3 (de) | 2007-10-31 |
AU1235692A (en) | 1992-08-27 |
ES2145744T5 (es) | 2008-02-01 |
JP2864434B2 (ja) | 1999-03-03 |
KR100234520B1 (ko) | 1999-12-15 |
EP0567566A1 (en) | 1993-11-03 |
JPH11199505A (ja) | 1999-07-27 |
EP0567566A4 (en) | 1994-10-05 |
ES2145744T3 (es) | 2000-07-16 |
NO932610D0 (no) | 1993-07-19 |
NO316310B1 (no) | 2004-01-12 |
WO1992013095A1 (en) | 1992-08-06 |
DE69230789T2 (de) | 2000-08-31 |
SG63617A1 (en) | 1999-03-30 |
GEP20002142B (en) | 2000-06-25 |
EP0567566B2 (en) | 2007-07-04 |
GR3033327T3 (en) | 2000-09-29 |
JP3210629B2 (ja) | 2001-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06506446A (ja) | 腫瘍壊死因子媒介疾患の治療方法 | |
AU672606B2 (en) | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases | |
RU2496514C2 (ru) | Применение пэгилированных интерферонов типа iii для лечения гепатита с | |
ES2334773T3 (es) | Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis. | |
KR20150121715A (ko) | Csf1 치료제 | |
JP6858305B2 (ja) | 関節リウマチを予防及び治療するための薬物の製造における選択性tnfr1拮抗ペプチドの使用 | |
EP3065765B1 (en) | Use of il-22 dimers in manufacture of medicaments for treating pancreatitis | |
RU2627451C2 (ru) | Противовоспалительные композиции | |
JP2021525234A (ja) | 疾患の治療に関する組成物および方法 | |
ES2438096T3 (es) | Utilización de péptidos tipo LPA para el tratamiento de enfermedades inflamatorias intestinales y diabetes tipo 1 | |
JP4912306B2 (ja) | ヒトil−18を投与することによって創傷を治癒する方法 | |
JP2002371006A (ja) | 肺線維症予防および/または進行防止剤 | |
JP2022066353A (ja) | 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 | |
US20160000875A1 (en) | Gm-csf for treatment of chronic oral mucositis | |
AU784768B2 (en) | Methods for treating cytokine mediated diseases | |
JP2020527573A (ja) | 強皮症関連血管障害を治療または改善するための組成物および方法 | |
WO2023196532A1 (en) | Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use | |
Towns et al. | Inhibition of Interleukin-1 as a Strategy for the Treatment of Rheumatoid Arthritis | |
Nordström | Anakinra in the treatment of rheumatoid arthritis and other IL-1-driven conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071218 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081218 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091218 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101218 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111218 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 14 |